Ari Arzu
Department of Respiratory Care, Texas State University, College of Health Professions, 601 University Drive, San Marcos, Texas 78666, United States.
Curr Pharm Biotechnol. 2017;18(11):877-882. doi: 10.2174/1389201019666171219104217.
High flow nasal cannula (HFNC) is widely utilized to support critically ill adults, pediatrics and neonates. Through the continuous delivery of oxygen at high flow rates that meet or exceed patients' inspiratory flow, HFNC improves oxygenation, respiratory rates, patient comfort, and tolerance during therapy. As HFNC becomes more widely employed, clinicians have started to consider aerosol drug delivery through HFNC.
Using HFNC along with nebulizers as a potential therapy in aerosol medicine is a new and innovative approach for aerosol drug delivery to patients with pulmonary diseases. The purpose of this paper is to review current in vitro and in vivo studies on aerosol drug delivery through HFNC in adults and children.
高流量鼻导管（HFNC）被广泛用于支持重症成人、儿童和新生儿。通过以满足或超过患者吸气流量的高流速持续输送氧气，HFNC可改善氧合、呼吸频率、患者舒适度以及治疗期间的耐受性。随着HFNC的应用越来越广泛，临床医生已开始考虑通过HFNC进行雾化药物输送。
将HFNC与雾化器结合作为雾化医学中的一种潜在治疗方法，是向肺部疾病患者输送雾化药物的一种新的创新方法。本文的目的是综述目前关于成人和儿童通过HFNC进行雾化药物输送的体外和体内研究。
